---
title: "Milestone Pharmaceuticals (MIST) Gets a Buy from Wells Fargo"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295788250.md"
description: "Wells Fargo analyst Mohit Bansal maintained a Buy rating on Milestone Pharmaceuticals (MIST) with a $7.00 price target. This follows H.C. Wainwright reiterating a Buy rating yesterday with an $8.00 target. Bansal, who covers the Healthcare sector, has an 11.2% average return and 60.68% success rate on recommendations."
datetime: "2026-08-13T11:06:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295788250.md)
  - [en](https://longbridge.com/en/news/295788250.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295788250.md)
generator: "portal-rs"
---

# Milestone Pharmaceuticals (MIST) Gets a Buy from Wells Fargo

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Milestone Pharmaceuticals, with a price target of $7.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Bansal covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Pfizer. According to TipRanks, Bansal has an average return of 11.2% and a 60.68% success rate on recommended stocks. 

In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.

### Related Stocks

- [MIST.US](https://longbridge.com/en/quote/MIST.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Milestone Pharmaceuticals enrolls first patient in Phase 3 ReVeRA-301 trial of etripamil nasal spray for AFib-RVR](https://longbridge.com/en/news/296615047.md)
- [MIST: CARDAMYST prescriptions and coverage surged post-launch, with strong clinical and regulatory momentum](https://longbridge.com/en/news/295658630.md)
- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [Telsey Advisory Sticks to Their Buy Rating for Abercrombie Fitch (ANF)](https://longbridge.com/en/news/296366488.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**